Marijuana: A Primer
 Russo et al. 2008. Phytochemical and genetic analyses of ancient cannabis from central Asia. Journal of Experimental Botany 59: 4171-4182.
 Pacher et al. 2006. The endocannbinoid system as an emerging target of pharmacotherapy. Pharmaceutical Reviews 58: 389-462.
 Izzo et al. 2009. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences 30: 515-527.
 Chen et al. 2010. Analytical characterization of Hempseed oil from eight regions in China. Journal of Dietary Supplements 2: 117-129.
 Mitch Earleywine. Understanding Marijuana: A New Look at the Scientific Evidence. Oxford University Press: 2002.
 Ethan Russo. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinology Letters 25: 31-39.
 Pacher et al. Op cit.
 Wayne Hall. A comparative appraisal of the health and psychological consequences of alcohol, cannabis, nicotine, and opiate use. National Drug and Alcohol Research Centre, University of New South Wales, 1995.
 Earleywine. Page 143. Op cit.
 Wang et al. 2008. Adverse effects of medical cannabinoids: A systemic review. CMAJ 178: 1669-1678.
 Hampson et al. 1998. Cannabidiol and THC are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95: 8268-8273.
 Sarfarez et al. 2008. Cannabinoids for cancer treatment: progress and promise. The Journal of Cancer Research 68: 339-342.
 Joy et al. Marijuana and Medicine: Assessing the Science Base. National Academy Press, 1999. Page 5.
 Pletcher et al. 2012. Association between marijuana exposure and pulmonary function over 20 years. JAMA 307: 173-181.
 Hashibe et al. 2006. Marijuana use and the risk of lung cancer and upper aerodigestive tract cancer: results of a population-based, case-control study. Cancer Epidemiology, Biomarkers, and Prevention 15: 1829-1834.
 Chaiton et al., 2021. Are vaporizers a lower risk alternative to smoking cannabis? Canadian Journal of Public Health [online ahead of print].
 Hazekamp et al. 2006. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences 95: 1308-1317.
 Abrams et al. 2007. Vaporization as a smokeless cannabis delivery system: a pilot study. Clinical pharmacology and therapeutics 82: 572-578.
 Spindle et al. 2019. Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid. Journal of Analytical Toxicology.